Cart (0 Items)
Your cart is currently empty.
View ProductsIt looks like you are visiting from outside the EU. Switch to the US version to see local pricing in USD and local shipping.
Switch to US ($)
Antibody-antibiotic conjugates (AACs) are an emerging class of biotherapeutics for the treatment of infectious diseases. With the rise of antibiotic resistance, this new class of drugs is expected to gain…
Antibody-enzyme conjugates represent a small but growing field of study within the vast topic of payloads for antibody-drug conjugate… Read More
When conjugated to antibodies and used in combinatorial therapeutic applications, protein toxins are typically referred to as fusion proteins or… Read More
DNA-damaging agents are one of the major classes of payloads used in antibody-drug conjugate (ADC) development. Unlike tubulin inhibitors, most… Read More
Experts believe that most challenges tied to the production of ADCs can be overcome by creating better linkers for… Read More
Payloads are the pharmaceutical component of antibody-drug conjugates (ADCs). Often these components are small drugs too toxic to be administered… Read More
Antibody-drug conjugates (ADCs) are an emerging class of pharmaceuticals designed to deliver highly toxic cargoes (payloads) to clinical targets. Read More
Cleavable linkers are a major class of linkers used in ADC development. As their name indicates, they have inbuilt… Read More
Different linker chemistry approaches have been developed since the inception of ADCs. Currently, cleavable and non-cleavable linkers are the… Read More
Antibody-drug conjugate linker chemistry has greatly evolved since the development of the first molecules. Linkers can be defined as… Read More